Communications Medicine (Oct 2022)

Data-driven analysis of a validated risk score for ovarian cancer identifies clinically distinct patterns during follow-up and treatment

  • Stefan Enroth,
  • Emma Ivansson,
  • Julia Hedlund Lindberg,
  • Maria Lycke,
  • Jessica Bergman,
  • Anna Reneland,
  • Karin Stålberg,
  • Karin Sundfeldt,
  • Ulf Gyllensten

DOI
https://doi.org/10.1038/s43856-022-00193-6
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 13

Abstract

Read online

Enroth et al. validate their previously developed 11-biomarker plasma protein-based risk-score for distinguishing benign vs. malignant ovarian tumors. The risk score is found to be informative of treatment outcome and predictive of 5-year survival.